InsidersTradesSigma
Total declarations
Companies
▲ Purchases (0 ops.)
▼ Sales (2 ops.)
Insider track record
CEODisclosed buys
0
Disclosed sells
2
Not enough buy signals with a settled T+90 horizon to measure a track record yet.
Signal history
Explore the full record of transactions filed by Baum Charles M, Chairman & CEO. Insider active across 2 companies, notably Mirati Therapeutics, Inc.. Cumulatively, 18 filings have been recorded. Split: 0 buy · 2 sells. Total volume traded: €690k. Activity tracked since 18 June 2021. The latest transaction was disclosed on 17 June 2024 (Attribution). Regulator: SEC (Form 4). The full history is openly available.
Companies and markets linked to Baum Charles M
Open company profiles for insider transactions, fundamentals and analyst consensus when available.
Declarations18 total
78,600 sharesCommon StockSEC:0001415889-25-001085:0
19,650 shares0Common StockSEC:0000950170-24-074864:0
123,389 sharesCommon StockSEC:0001140361-24-003528:0
94,057 sharesCommon StockSEC:0001140361-24-003528:1
20,425 sharesCommon StockSEC:0001140361-24-003528:2
20,425 shares@ US$58.7516.5% of flowCommon StockSEC:0001628280-24-000277:0
54,054 shares@ US$37.0027.7% of flowCommon StockSEC:0001628280-23-028884:0
19,650 shares0Common StockSEC:0000950170-23-028605:0
4,444 shares0Common StockSEC:0001214659-23-001049:0
3,648 shares@ US$46.602.5% of flowCommon StockSEC:0001214659-23-000290:0
53,618 shares0Common StockSEC:0001214659-22-015200:0
69,256 shares@ US$17.4117.7% of flowCommon StockSEC:0001214659-22-014229:0
39,300 shares0Common StockSEC:0001209191-22-037669:0
25,543 shares0Common StockSEC:0001214659-22-000856:0
4,045 shares@ US$147.739.8% of flowCommon StockSEC:0001214659-22-000419:0
7,430 shares0Common StockSEC:0001214659-21-013378:0
47,204 shares@ US$8.496.6% of flowCommon StockSEC:0001214659-21-012712:0
40,000 shares@ US$8.495.3% of flowCommon StockSEC:0001214659-21-006762:0
18 of 18 declarations
About Baum Charles M
BAUM CHARLES M is Président-Directeur Général. He has 18 filings in total. Across the 18 sampled filings, sales amount to EUR 689899, over the period from 2021-06-21 to 2025-01-08, and the main filings concern Mirati Therapeutics, Inc.
